Insmed (INSM) Change in Accured Expenses (2010 - 2026)
Insmed (INSM) posted quarterly Change in Accured Expenses of -$33.9 million for Q1 2026, up 44.91% year-over-year from -$23.4 million in Q1 2025, and down 137.49% quarter-over-quarter from $90.3 million in Q4 2025.
Insmed (INSM) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Insmed's Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$33.9 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 44.91% year-over-year to -$33.9 million; the TTM figure through Mar 2026 stood at $127.7 million (up 726.62% YoY), while the FY2025 annual figure was $100.1 million, up 124.42% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$33.9 million, down from $90.3 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $90.3 million in Q4 2025, with the low at -$61.5 million in Q1 2025.
- The 5-year median for Change in Accured Expenses is -$620000.0 (2024), against an average of $5.1 million.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses sank 2174.61% in 2024, then surged 7448.23% in 2025.
- Insmed's Change in Accured Expenses stood at -$27.7 million in 2022, then jumped by 84.0% to -$4.4 million in 2023, then jumped by 1271.85% to $52.0 million in 2024, then soared by 73.88% to $90.3 million in 2025, then slumped by 137.49% to -$33.9 million in 2026.
- Business Quant data shows INSM's Change in Accured Expenses at -$33.9 million in Q1 2026, $90.3 million in Q4 2025, and $45.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -13.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68.82 Mn |
| Jun 30, 2026 | 68.82 Mn |
| Mar 31, 2026 | -33.88 Mn |
| Mar 31, 2026 | -33.88 Mn |
| Dec 31, 2025 | 90.35 Mn |
| Dec 31, 2025 | 90.35 Mn |
| Sep 30, 2025 | 45.56 Mn |
| Sep 30, 2025 | 45.56 Mn |
| Jun 30, 2025 | 25.66 Mn |
| Jun 30, 2025 | 25.66 Mn |
| Mar 31, 2025 | -61.49 Mn |
| Mar 31, 2025 | -61.49 Mn |
| Dec 31, 2024 | 51.96 Mn |
| Dec 31, 2024 | 51.96 Mn |
| Sep 30, 2024 | -620,000.00 |
| Sep 30, 2024 | -620,000.00 |
| Jun 30, 2024 | 25.60 Mn |
| Jun 30, 2024 | 25.60 Mn |
| Mar 31, 2024 | -32.35 Mn |
| Mar 31, 2024 | -32.35 Mn |